Signet-ring cell carcinoma of the prostate effectively treated with maximal androgen blockade.
Primary signet-ring cell carcinoma (SRCC) of the prostate is very rare and has a poor prognosis, even when treated with aggressive therapy. We report herein a case of a 72-year-old man with prostatic SRCC. The patient had a tumor that extended directly to the rectum. Maximal androgen blockade was started and 20 months later, the patient was alive without evidence of recurrence. The present case of prostatic SRCC responded well to medical therapy, however, tumors can recur after a long period of time. Therefore, adjuvant therapy is recommended.
Akagashi
Keigo
K
Department of Urology, Sanjukai Hospital, Sapporo, Hokkaido, Japan. akagashi@sanjukai.or.jp
Tanda
Hitoshi
H
Kato
Shuji
S
Ohnishi
Shigeki
S
Nakajima
Hisao
H
Nanbu
Akihito
A
Nitta
Toshikazu
T
Koroku
Mikio
M
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D018279:Carcinoma, Signet Ring Cell / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen; D016729:Leuprolide